Nested Therapeutics

Executive Summary

Nested Therapeutics is a preclinical biotechnology company pioneering a novel allosteric targeting platform to address historically undruggable cancer targets. Founded in 2020 and headquartered in Cambridge, MA, the company has raised $90 million to advance its precision oncology pipeline. Its proprietary platform identifies small molecule modulators of allosteric sites on oncogenic proteins, enabling the development of therapies for genetically defined cancers with high unmet need. While the company remains in early preclinical stages, its approach has the potential to unlock new therapeutic avenues beyond conventional target inhibition. The company's progress will depend on successful completion of IND-enabling studies and securing additional financing to support clinical development.

Upcoming Catalysts (preview)

• Q3 2026Lead Program IND Filing40% success
• Q2 2026Series B Financing Announcement70% success
• Q2 2026Preclinical Data Presentation at Major Oncology Conference80% success